WO2014102693A1 - Composition pharmaceutique contenant un derive de n-phenylpyrazole et de permethrine, utilisation pour la preparation d'un medicament veterinaire topique - Google Patents
Composition pharmaceutique contenant un derive de n-phenylpyrazole et de permethrine, utilisation pour la preparation d'un medicament veterinaire topique Download PDFInfo
- Publication number
- WO2014102693A1 WO2014102693A1 PCT/IB2013/061218 IB2013061218W WO2014102693A1 WO 2014102693 A1 WO2014102693 A1 WO 2014102693A1 IB 2013061218 W IB2013061218 W IB 2013061218W WO 2014102693 A1 WO2014102693 A1 WO 2014102693A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pharmaceutical composition
- volume
- weight
- permethrin
- topical veterinary
- Prior art date
Links
- RLLPVAHGXHCWKJ-UHFFFAOYSA-N permethrin Chemical compound CC1(C)C(C=C(Cl)Cl)C1C(=O)OCC1=CC=CC(OC=2C=CC=CC=2)=C1 RLLPVAHGXHCWKJ-UHFFFAOYSA-N 0.000 title claims abstract description 35
- 229960000490 permethrin Drugs 0.000 title claims abstract description 33
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 19
- 230000000699 topical effect Effects 0.000 title claims abstract description 18
- WITMXBRCQWOZPX-UHFFFAOYSA-N 1-phenylpyrazole Chemical class C1=CC=NN1C1=CC=CC=C1 WITMXBRCQWOZPX-UHFFFAOYSA-N 0.000 title claims abstract description 16
- 239000003814 drug Substances 0.000 title description 5
- 239000000203 mixture Substances 0.000 claims abstract description 84
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims abstract description 66
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 28
- 235000019445 benzyl alcohol Nutrition 0.000 claims abstract description 22
- 239000003112 inhibitor Substances 0.000 claims abstract description 10
- 206010061217 Infestation Diseases 0.000 claims abstract description 8
- 238000011282 treatment Methods 0.000 claims abstract description 8
- 244000045947 parasite Species 0.000 claims abstract description 7
- 230000002265 prevention Effects 0.000 claims abstract description 4
- ZOCSXAVNDGMNBV-UHFFFAOYSA-N 5-amino-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-4-[(trifluoromethyl)sulfinyl]-1H-pyrazole-3-carbonitrile Chemical compound NC1=C(S(=O)C(F)(F)F)C(C#N)=NN1C1=C(Cl)C=C(C(F)(F)F)C=C1Cl ZOCSXAVNDGMNBV-UHFFFAOYSA-N 0.000 claims description 23
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 claims description 21
- 239000005899 Fipronil Substances 0.000 claims description 21
- 229960004217 benzyl alcohol Drugs 0.000 claims description 21
- 229940013764 fipronil Drugs 0.000 claims description 21
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 claims description 16
- 241001465754 Metazoa Species 0.000 claims description 15
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 claims description 13
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 claims description 12
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 9
- 239000003960 organic solvent Substances 0.000 claims description 8
- 239000004322 Butylated hydroxytoluene Substances 0.000 claims description 6
- 239000013543 active substance Substances 0.000 claims description 6
- 239000003963 antioxidant agent Substances 0.000 claims description 6
- 235000010354 butylated hydroxytoluene Nutrition 0.000 claims description 6
- 229940095259 butylated hydroxytoluene Drugs 0.000 claims description 6
- 235000006708 antioxidants Nutrition 0.000 claims description 5
- 235000019282 butylated hydroxyanisole Nutrition 0.000 claims description 5
- 239000004544 spot-on Substances 0.000 claims description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 4
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 claims description 4
- ARXJGSRGQADJSQ-UHFFFAOYSA-N 1-methoxypropan-2-ol Chemical compound COCC(C)O ARXJGSRGQADJSQ-UHFFFAOYSA-N 0.000 claims description 3
- WMDZKDKPYCNCDZ-UHFFFAOYSA-N 2-(2-butoxypropoxy)propan-1-ol Chemical compound CCCCOC(C)COC(C)CO WMDZKDKPYCNCDZ-UHFFFAOYSA-N 0.000 claims description 3
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 claims description 3
- ZNQVEEAIQZEUHB-UHFFFAOYSA-N 2-ethoxyethanol Chemical compound CCOCCO ZNQVEEAIQZEUHB-UHFFFAOYSA-N 0.000 claims description 3
- 239000004262 Ethyl gallate Substances 0.000 claims description 2
- VFPFQHQNJCMNBZ-UHFFFAOYSA-N Ethyl gallate Natural products CCOC(=O)C1=CC(O)=C(O)C(O)=C1 VFPFQHQNJCMNBZ-UHFFFAOYSA-N 0.000 claims description 2
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 claims description 2
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 claims description 2
- 239000005927 Pyriproxyfen Substances 0.000 claims description 2
- 230000003078 antioxidant effect Effects 0.000 claims description 2
- 235000010323 ascorbic acid Nutrition 0.000 claims description 2
- 239000011668 ascorbic acid Substances 0.000 claims description 2
- 229960005070 ascorbic acid Drugs 0.000 claims description 2
- 235000010385 ascorbyl palmitate Nutrition 0.000 claims description 2
- 235000019277 ethyl gallate Nutrition 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 235000010388 propyl gallate Nutrition 0.000 claims description 2
- 239000000473 propyl gallate Substances 0.000 claims description 2
- 229940075579 propyl gallate Drugs 0.000 claims description 2
- NHDHVHZZCFYRSB-UHFFFAOYSA-N pyriproxyfen Chemical compound C=1C=CC=NC=1OC(C)COC(C=C1)=CC=C1OC1=CC=CC=C1 NHDHVHZZCFYRSB-UHFFFAOYSA-N 0.000 claims description 2
- 239000004255 Butylated hydroxyanisole Substances 0.000 claims 3
- 229940043253 butylated hydroxyanisole Drugs 0.000 claims 3
- 229960001295 tocopherol Drugs 0.000 claims 1
- 239000011732 tocopherol Substances 0.000 claims 1
- 239000000243 solution Substances 0.000 description 38
- 238000002425 crystallisation Methods 0.000 description 24
- 230000008025 crystallization Effects 0.000 description 24
- 238000009472 formulation Methods 0.000 description 19
- 239000002728 pyrethroid Substances 0.000 description 14
- 241000258242 Siphonaptera Species 0.000 description 11
- 241000282472 Canis lupus familiaris Species 0.000 description 10
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 9
- 239000004480 active ingredient Substances 0.000 description 7
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 7
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 7
- 229920000053 polysorbate 80 Polymers 0.000 description 7
- 229940068968 polysorbate 80 Drugs 0.000 description 7
- -1 aliphatic cyclic carbonate Chemical class 0.000 description 6
- 241000238876 Acari Species 0.000 description 5
- 206010020751 Hypersensitivity Diseases 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 239000013078 crystal Substances 0.000 description 5
- 206010003645 Atopy Diseases 0.000 description 4
- 241000238631 Hexapoda Species 0.000 description 4
- 239000004743 Polypropylene Substances 0.000 description 4
- 208000003251 Pruritus Diseases 0.000 description 4
- 208000026935 allergic disease Diseases 0.000 description 4
- 230000007815 allergy Effects 0.000 description 4
- 239000011549 crystallization solution Substances 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- KAICRBBQCRKMPO-UHFFFAOYSA-N phosphoric acid;pyridine-3,4-diamine Chemical compound OP(O)(O)=O.NC1=CC=NC=C1N KAICRBBQCRKMPO-UHFFFAOYSA-N 0.000 description 4
- 229920001155 polypropylene Polymers 0.000 description 4
- 150000003505 terpenes Chemical class 0.000 description 4
- 235000007586 terpenes Nutrition 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- 201000004624 Dermatitis Diseases 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 241000255925 Diptera Species 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 241000282414 Homo sapiens Species 0.000 description 3
- 241000255129 Phlebotominae Species 0.000 description 3
- 230000002141 anti-parasite Effects 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 208000017520 skin disease Diseases 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 229920001824 Barex® Polymers 0.000 description 2
- 241000490513 Ctenocephalides canis Species 0.000 description 2
- 241000258924 Ctenocephalides felis Species 0.000 description 2
- 206010012438 Dermatitis atopic Diseases 0.000 description 2
- ZDQWESQEGGJUCH-UHFFFAOYSA-N Diisopropyl adipate Chemical compound CC(C)OC(=O)CCCCC(=O)OC(C)C ZDQWESQEGGJUCH-UHFFFAOYSA-N 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- 241000509416 Sarcoptes Species 0.000 description 2
- 241000607479 Yersinia pestis Species 0.000 description 2
- 238000001720 action spectrum Methods 0.000 description 2
- 239000003096 antiparasitic agent Substances 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- 201000008680 babesiosis Diseases 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000002949 juvenile hormone Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 229920000139 polyethylene terephthalate Polymers 0.000 description 2
- 239000005020 polyethylene terephthalate Substances 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 229950008882 polysorbate Drugs 0.000 description 2
- 230000007928 solubilization Effects 0.000 description 2
- 238000005063 solubilization Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- FZRBKIRIBLNOAM-UHFFFAOYSA-N (E,E)-2-propynyl 3,7,11-trimethyl-2,4-dodecadienoate Chemical compound CC(C)CCCC(C)CC=CC(C)=CC(=O)OCC#C FZRBKIRIBLNOAM-UHFFFAOYSA-N 0.000 description 1
- PCKNFPQPGUWFHO-SXBRIOAWSA-N (Z)-flucycloxuron Chemical compound FC1=CC=CC(F)=C1C(=O)NC(=O)NC(C=C1)=CC=C1CO\N=C(C=1C=CC(Cl)=CC=1)\C1CC1 PCKNFPQPGUWFHO-SXBRIOAWSA-N 0.000 description 1
- MIZLGWKEZAPEFJ-UHFFFAOYSA-N 1,1,2-trifluoroethene Chemical group FC=C(F)F MIZLGWKEZAPEFJ-UHFFFAOYSA-N 0.000 description 1
- FSOSASZVRFABOM-UHFFFAOYSA-N 1-(trifluoromethylsulfinyl)pyrazole-3-carbonitrile Chemical compound FC(F)(F)S(=O)N1C=CC(C#N)=N1 FSOSASZVRFABOM-UHFFFAOYSA-N 0.000 description 1
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
- FSVJFNAIGNNGKK-UHFFFAOYSA-N 2-[cyclohexyl(oxo)methyl]-3,6,7,11b-tetrahydro-1H-pyrazino[2,1-a]isoquinolin-4-one Chemical compound C1C(C2=CC=CC=C2CC2)N2C(=O)CN1C(=O)C1CCCCC1 FSVJFNAIGNNGKK-UHFFFAOYSA-N 0.000 description 1
- ZDOOQPFIGYHZFV-UHFFFAOYSA-N 2-ethyl-4-[(4-phenoxyphenoxy)methyl]-1,3-dioxolane Chemical compound O1C(CC)OCC1COC(C=C1)=CC=C1OC1=CC=CC=C1 ZDOOQPFIGYHZFV-UHFFFAOYSA-N 0.000 description 1
- AZSNMRSAGSSBNP-UHFFFAOYSA-N 22,23-dihydroavermectin B1a Natural products C1CC(C)C(C(C)CC)OC21OC(CC=C(C)C(OC1OC(C)C(OC3OC(C)C(O)C(OC)C3)C(OC)C1)C(C)C=CC=C1C3(C(C(=O)O4)C=C(C)C(O)C3OC1)O)CC4C2 AZSNMRSAGSSBNP-UHFFFAOYSA-N 0.000 description 1
- SPBDXSGPUHCETR-JFUDTMANSA-N 8883yp2r6d Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O[C@@H]([C@@H](C)CC4)C(C)C)O3)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C.C1C[C@H](C)[C@@H]([C@@H](C)CC)O[C@@]21O[C@H](C\C=C(C)\[C@@H](O[C@@H]1O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C1)[C@@H](C)\C=C\C=C/1[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\1)O)C[C@H]4C2 SPBDXSGPUHCETR-JFUDTMANSA-N 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 241001524031 Aedes sp. Species 0.000 description 1
- 241000238679 Amblyomma Species 0.000 description 1
- 206010068172 Anal pruritus Diseases 0.000 description 1
- 241001520752 Anopheles sp. Species 0.000 description 1
- 206010003399 Arthropod bite Diseases 0.000 description 1
- 239000005878 Azadirachtin Substances 0.000 description 1
- 241001490776 Babesia sp. Species 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 241000258922 Ctenocephalides Species 0.000 description 1
- 241000256054 Culex <genus> Species 0.000 description 1
- 239000005891 Cyromazine Substances 0.000 description 1
- 241001128004 Demodex Species 0.000 description 1
- 241001480824 Dermacentor Species 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- 239000005893 Diflubenzuron Substances 0.000 description 1
- 241000935792 Dipylidium caninum Species 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 239000005898 Fenoxycarb Substances 0.000 description 1
- 208000006004 Flea Infestations Diseases 0.000 description 1
- 239000005906 Imidacloprid Substances 0.000 description 1
- 239000005907 Indoxacarb Substances 0.000 description 1
- 241000238681 Ixodes Species 0.000 description 1
- 208000004554 Leishmaniasis Diseases 0.000 description 1
- 239000005912 Lufenuron Substances 0.000 description 1
- 208000016604 Lyme disease Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 239000005914 Metaflumizone Substances 0.000 description 1
- MIFOMMKAVSCNKQ-HWIUFGAZSA-N Metaflumizone Chemical compound C1=CC(OC(F)(F)F)=CC=C1NC(=O)N\N=C(C=1C=C(C=CC=1)C(F)(F)F)\CC1=CC=C(C#N)C=C1 MIFOMMKAVSCNKQ-HWIUFGAZSA-N 0.000 description 1
- 241000790250 Otodectes Species 0.000 description 1
- 241000722350 Phlebotomus <genus> Species 0.000 description 1
- 241000224016 Plasmodium Species 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 229920001328 Polyvinylidene chloride Polymers 0.000 description 1
- MWMQNVGAHVXSPE-UHFFFAOYSA-N Pyriprole Chemical compound ClC=1C=C(C(F)(F)F)C=C(Cl)C=1N1N=C(C#N)C(SC(F)F)=C1NCC1=CC=CC=N1 MWMQNVGAHVXSPE-UHFFFAOYSA-N 0.000 description 1
- 241001481703 Rhipicephalus <genus> Species 0.000 description 1
- 208000034712 Rickettsia Infections Diseases 0.000 description 1
- 241000319984 Sarcoptes sp. Species 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 239000005929 Spinetoram Substances 0.000 description 1
- GOENIMGKWNZVDA-OAMCMWGQSA-N Spinetoram Chemical compound CO[C@@H]1[C@H](OCC)[C@@H](OC)[C@H](C)O[C@H]1OC1C[C@H]2[C@@H]3C=C4C(=O)[C@H](C)[C@@H](O[C@@H]5O[C@H](C)[C@H](CC5)N(C)C)CCC[C@H](CC)OC(=O)CC4[C@@H]3CC[C@@H]2C1 GOENIMGKWNZVDA-OAMCMWGQSA-N 0.000 description 1
- 239000005938 Teflubenzuron Substances 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- 208000035472 Zoonoses Diseases 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 230000002506 adulticidal effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 229960002587 amitraz Drugs 0.000 description 1
- QXAITBQSYVNQDR-ZIOPAAQOSA-N amitraz Chemical compound C=1C=C(C)C=C(C)C=1/N=C/N(C)\C=N\C1=CC=C(C)C=C1C QXAITBQSYVNQDR-ZIOPAAQOSA-N 0.000 description 1
- 210000003503 anal sac Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- VEHPJKVTJQSSKL-UHFFFAOYSA-N azadirachtin Natural products O1C2(C)C(C3(C=COC3O3)O)CC3C21C1(C)C(O)C(OCC2(OC(C)=O)C(CC3OC(=O)C(C)=CC)OC(C)=O)C2C32COC(C(=O)OC)(O)C12 VEHPJKVTJQSSKL-UHFFFAOYSA-N 0.000 description 1
- FTNJWQUOZFUQQJ-NDAWSKJSSA-N azadirachtin A Chemical compound C([C@@H]([C@]1(C=CO[C@H]1O1)O)[C@]2(C)O3)[C@H]1[C@]23[C@]1(C)[C@H](O)[C@H](OC[C@@]2([C@@H](C[C@@H]3OC(=O)C(\C)=C\C)OC(C)=O)C(=O)OC)[C@@H]2[C@]32CO[C@@](C(=O)OC)(O)[C@@H]12 FTNJWQUOZFUQQJ-NDAWSKJSSA-N 0.000 description 1
- FTNJWQUOZFUQQJ-IRYYUVNJSA-N azadirachtin A Natural products C([C@@H]([C@]1(C=CO[C@H]1O1)O)[C@]2(C)O3)[C@H]1[C@]23[C@]1(C)[C@H](O)[C@H](OC[C@@]2([C@@H](C[C@@H]3OC(=O)C(\C)=C/C)OC(C)=O)C(=O)OC)[C@@H]2[C@]32CO[C@@](C(=O)OC)(O)[C@@H]12 FTNJWQUOZFUQQJ-IRYYUVNJSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- VEMKTZHHVJILDY-UXHICEINSA-N bioresmethrin Chemical compound CC1(C)[C@H](C=C(C)C)[C@H]1C(=O)OCC1=COC(CC=2C=CC=CC=2)=C1 VEMKTZHHVJILDY-UXHICEINSA-N 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- UISUNVFOGSJSKD-UHFFFAOYSA-N chlorfluazuron Chemical compound FC1=CC=CC(F)=C1C(=O)NC(=O)NC(C=C1Cl)=CC(Cl)=C1OC1=NC=C(C(F)(F)F)C=C1Cl UISUNVFOGSJSKD-UHFFFAOYSA-N 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 230000002089 crippling effect Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 150000001925 cycloalkenes Chemical class 0.000 description 1
- LVQDKIWDGQRHTE-UHFFFAOYSA-N cyromazine Chemical compound NC1=NC(N)=NC(NC2CC2)=N1 LVQDKIWDGQRHTE-UHFFFAOYSA-N 0.000 description 1
- 229950000775 cyromazine Drugs 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- QQQYTWIFVNKMRW-UHFFFAOYSA-N diflubenzuron Chemical compound FC1=CC=CC(F)=C1C(=O)NC(=O)NC1=CC=C(Cl)C=C1 QQQYTWIFVNKMRW-UHFFFAOYSA-N 0.000 description 1
- 229940019503 diflubenzuron Drugs 0.000 description 1
- APMCZEMFQVQTHY-AGACNZRVSA-N dimethyl (1S,4S,5R,6S,7S,8R,11S,12R,14S,15R)-12-acetyloxy-4,7-dihydroxy-6-[(1S,2S,6S,8S,9R,11S)-2-hydroxy-11-methyl-5,7,10-trioxatetracyclo[6.3.1.02,6.09,11]dodecan-9-yl]-6-methyl-14-(2-methylbutanoyloxy)-3,9-dioxatetracyclo[6.6.1.01,5.011,15]pentadecane-4,11-dicarboxylate Chemical compound C([C@@H]([C@]1(CCO[C@H]1O1)O)[C@]2(C)O3)[C@H]1[C@]23[C@](C)([C@@H]1O)[C@@H]2[C@@](O)(C(=O)OC)OC[C@@]32[C@H]2[C@H]1OC[C@]2(C(=O)OC)[C@H](OC(C)=O)C[C@@H]3OC(=O)C(C)CC APMCZEMFQVQTHY-AGACNZRVSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 244000078703 ectoparasite Species 0.000 description 1
- 230000001984 ectoparasiticidal effect Effects 0.000 description 1
- 239000013057 ectoparasiticide Substances 0.000 description 1
- ZMQMTKVVAMWKNY-YSXLEBCMSA-N emodepside Chemical compound C([C@@H]1C(=O)N(C)[C@@H](CC(C)C)C(=O)O[C@H](C)C(=O)N(C)[C@H](C(O[C@H](CC=2C=CC(=CC=2)N2CCOCC2)C(=O)N(C)[C@@H](CC(C)C)C(=O)O[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)O1)=O)CC(C)C)C(C=C1)=CC=C1N1CCOCC1 ZMQMTKVVAMWKNY-YSXLEBCMSA-N 0.000 description 1
- 229960001575 emodepside Drugs 0.000 description 1
- 108010056417 emodepside Proteins 0.000 description 1
- HJUFTIJOISQSKQ-UHFFFAOYSA-N fenoxycarb Chemical compound C1=CC(OCCNC(=O)OCC)=CC=C1OC1=CC=CC=C1 HJUFTIJOISQSKQ-UHFFFAOYSA-N 0.000 description 1
- YOWNVPAUWYHLQX-UHFFFAOYSA-N fluazuron Chemical compound FC1=CC=CC(F)=C1C(=O)NC(=O)NC1=CC=C(Cl)C(OC=2C(=CC(=CN=2)C(F)(F)F)Cl)=C1 YOWNVPAUWYHLQX-UHFFFAOYSA-N 0.000 description 1
- 229950006719 fluazuron Drugs 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000003966 growth inhibitor Substances 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 244000000013 helminth Species 0.000 description 1
- FYQGBXGJFWXIPP-UHFFFAOYSA-N hydroprene Chemical compound CCOC(=O)C=C(C)C=CCC(C)CCCC(C)C FYQGBXGJFWXIPP-UHFFFAOYSA-N 0.000 description 1
- 229930000073 hydroprene Natural products 0.000 description 1
- 229940056881 imidacloprid Drugs 0.000 description 1
- YWTYJOPNNQFBPC-UHFFFAOYSA-N imidacloprid Chemical compound [O-][N+](=O)\N=C1/NCCN1CC1=CC=C(Cl)N=C1 YWTYJOPNNQFBPC-UHFFFAOYSA-N 0.000 description 1
- VBCVPMMZEGZULK-NRFANRHFSA-N indoxacarb Chemical compound C([C@@]1(OC2)C(=O)OC)C3=CC(Cl)=CC=C3C1=NN2C(=O)N(C(=O)OC)C1=CC=C(OC(F)(F)F)C=C1 VBCVPMMZEGZULK-NRFANRHFSA-N 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 150000002547 isoxazolines Chemical class 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 229960002418 ivermectin Drugs 0.000 description 1
- 230000009191 jumping Effects 0.000 description 1
- 229930014550 juvenile hormone Natural products 0.000 description 1
- 150000003633 juvenile hormone derivatives Chemical class 0.000 description 1
- 229930191400 juvenile hormones Natural products 0.000 description 1
- 229930001540 kinoprene Natural products 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 229960000521 lufenuron Drugs 0.000 description 1
- PWPJGUXAGUPAHP-UHFFFAOYSA-N lufenuron Chemical compound C1=C(Cl)C(OC(F)(F)C(C(F)(F)F)F)=CC(Cl)=C1NC(=O)NC(=O)C1=C(F)C=CC=C1F PWPJGUXAGUPAHP-UHFFFAOYSA-N 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 229930002897 methoprene Natural products 0.000 description 1
- 229950003442 methoprene Drugs 0.000 description 1
- FXWHFKOXMBTCMP-WMEDONTMSA-N milbemycin Natural products COC1C2OCC3=C/C=C/C(C)CC(=CCC4CC(CC5(O4)OC(C)C(C)C(OC(=O)C(C)CC(C)C)C5O)OC(=O)C(C=C1C)C23O)C FXWHFKOXMBTCMP-WMEDONTMSA-N 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- YZBLFMPOMVTDJY-CBYMMZEQSA-N moxidectin Chemical compound O1[C@H](C(\C)=C\C(C)C)[C@@H](C)C(=N/OC)\C[C@@]11O[C@H](C\C=C(C)\C[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 YZBLFMPOMVTDJY-CBYMMZEQSA-N 0.000 description 1
- 229960004816 moxidectin Drugs 0.000 description 1
- 231100000189 neurotoxic Toxicity 0.000 description 1
- 230000002887 neurotoxic effect Effects 0.000 description 1
- NJPPVKZQTLUDBO-UHFFFAOYSA-N novaluron Chemical compound C1=C(Cl)C(OC(F)(F)C(OC(F)(F)F)F)=CC=C1NC(=O)NC(=O)C1=C(F)C=CC=C1F NJPPVKZQTLUDBO-UHFFFAOYSA-N 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 229920002239 polyacrylonitrile Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 239000005033 polyvinylidene chloride Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 229960002957 praziquantel Drugs 0.000 description 1
- 244000062645 predators Species 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- RUOJZAUFBMNUDX-UHFFFAOYSA-N propylene carbonate Chemical compound CC1COC(=O)O1 RUOJZAUFBMNUDX-UHFFFAOYSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- AFJYYKSVHJGXSN-KAJWKRCWSA-N selamectin Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1C(/C)=C/C[C@@H](O[C@]2(O[C@@H]([C@@H](C)CC2)C2CCCCC2)C2)C[C@@H]2OC(=O)[C@@H]([C@]23O)C=C(C)C(=N\O)/[C@H]3OC\C2=C/C=C/[C@@H]1C AFJYYKSVHJGXSN-KAJWKRCWSA-N 0.000 description 1
- 229960002245 selamectin Drugs 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- CJDWRQLODFKPEL-UHFFFAOYSA-N teflubenzuron Chemical compound FC1=CC=CC(F)=C1C(=O)NC(=O)NC1=CC(Cl)=C(F)C(Cl)=C1F CJDWRQLODFKPEL-UHFFFAOYSA-N 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 206010048282 zoonosis Diseases 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A61K9/0017—Non-human animal skin, e.g. pour-on, spot-on
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/14—Ectoparasiticides, e.g. scabicides
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BR112015015493-0A BR112015015493B1 (pt) | 2012-12-27 | 2013-12-20 | Composição farmaceutica veterinaria e uso de uma composicao farmaceutica veterinaria |
AU2013368970A AU2013368970A1 (en) | 2012-12-27 | 2013-12-20 | Pharmaceutical composition containing a derivative of N-phenylpyrazole and permethrin, and use for the production of a topical veterinary medicament |
EP13826884.2A EP2938361A1 (fr) | 2012-12-27 | 2013-12-20 | Composition pharmaceutique contenant un derive de n-phenylpyrazole et de permethrine, utilisation pour la preparation d'un medicament veterinaire topique |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1262822A FR3000393B1 (fr) | 2012-12-27 | 2012-12-27 | Association topique d'un n-phenylpyrazole et de permethrine |
FR1262822 | 2012-12-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014102693A1 true WO2014102693A1 (fr) | 2014-07-03 |
Family
ID=48224910
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2013/061218 WO2014102693A1 (fr) | 2012-12-27 | 2013-12-20 | Composition pharmaceutique contenant un derive de n-phenylpyrazole et de permethrine, utilisation pour la preparation d'un medicament veterinaire topique |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP2938361A1 (fr) |
AU (1) | AU2013368970A1 (fr) |
BR (1) | BR112015015493B1 (fr) |
FR (1) | FR3000393B1 (fr) |
WO (1) | WO2014102693A1 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016108117A1 (fr) * | 2014-12-30 | 2016-07-07 | Virbac | Combinaison topique de fipronil, de perméthrine et de pyriproxyfène |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0295117A1 (fr) | 1987-06-12 | 1988-12-14 | Rhone-Poulenc Agriculture Limited | Dérivés de N-phénylpyrazoles |
EP0352944A1 (fr) | 1988-07-15 | 1990-01-31 | Rhone-Poulenc Agriculture Limited | Dérivés de N-phénylpyrazoles |
FR2739255A1 (fr) * | 1995-09-29 | 1997-04-04 | Rhone Merieux | Composition antiparasitaire pour le traitement et la protection des animaux de compagnie |
WO2002062326A1 (fr) * | 2001-02-08 | 2002-08-15 | Schering-Plough Ltd. | Compositions parasiticides et procedes d'utilisation de ces compositions |
WO2008080542A2 (fr) | 2006-12-27 | 2008-07-10 | Bayer Animal Health Gmbh | Produit de combinaison destiné à la lutte contre les parasites chez l'animal |
WO2009033175A1 (fr) | 2007-09-06 | 2009-03-12 | The Hartz Mountain Corporation | Procédé pour lutter contre les parasites des animaux en utilisant des régulateurs de croissance d'insectes |
WO2010070210A1 (fr) * | 2008-12-16 | 2010-06-24 | Virbac | Composition pharmaceutique contenant un derive de n-phenylpyrazole, utilisation pour la preparation d'un medicament veterinaire topique pour lutter contre les puces |
WO2011038024A1 (fr) | 2009-09-22 | 2011-03-31 | Sergeant's Pet Care Products, Inc. | Composition antiparasitaire à application localisée (spot-on) |
-
2012
- 2012-12-27 FR FR1262822A patent/FR3000393B1/fr active Active
-
2013
- 2013-12-20 WO PCT/IB2013/061218 patent/WO2014102693A1/fr active Application Filing
- 2013-12-20 AU AU2013368970A patent/AU2013368970A1/en not_active Abandoned
- 2013-12-20 BR BR112015015493-0A patent/BR112015015493B1/pt active IP Right Grant
- 2013-12-20 EP EP13826884.2A patent/EP2938361A1/fr not_active Withdrawn
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0295117A1 (fr) | 1987-06-12 | 1988-12-14 | Rhone-Poulenc Agriculture Limited | Dérivés de N-phénylpyrazoles |
EP0352944A1 (fr) | 1988-07-15 | 1990-01-31 | Rhone-Poulenc Agriculture Limited | Dérivés de N-phénylpyrazoles |
FR2739255A1 (fr) * | 1995-09-29 | 1997-04-04 | Rhone Merieux | Composition antiparasitaire pour le traitement et la protection des animaux de compagnie |
WO1997012521A1 (fr) | 1995-09-29 | 1997-04-10 | Rhone Merieux | Composition antiparasitaire pour le traitement et la protection des animaux de compagnie |
WO2002062326A1 (fr) * | 2001-02-08 | 2002-08-15 | Schering-Plough Ltd. | Compositions parasiticides et procedes d'utilisation de ces compositions |
EP1372622A1 (fr) | 2001-02-08 | 2004-01-02 | Schering-Plough Ltd. | Compositions parasiticides et procedes d'utilisation de ces compositions |
WO2008080542A2 (fr) | 2006-12-27 | 2008-07-10 | Bayer Animal Health Gmbh | Produit de combinaison destiné à la lutte contre les parasites chez l'animal |
US20100016398A1 (en) * | 2006-12-27 | 2010-01-21 | Bayer Animal Health Gmbh | Combination product for controlling parasites on animals |
WO2009033175A1 (fr) | 2007-09-06 | 2009-03-12 | The Hartz Mountain Corporation | Procédé pour lutter contre les parasites des animaux en utilisant des régulateurs de croissance d'insectes |
WO2010070210A1 (fr) * | 2008-12-16 | 2010-06-24 | Virbac | Composition pharmaceutique contenant un derive de n-phenylpyrazole, utilisation pour la preparation d'un medicament veterinaire topique pour lutter contre les puces |
WO2011038024A1 (fr) | 2009-09-22 | 2011-03-31 | Sergeant's Pet Care Products, Inc. | Composition antiparasitaire à application localisée (spot-on) |
Non-Patent Citations (3)
Title |
---|
ANONYMOUS: "Registration jacket for Effitix Topical Solution for Dogs, EPA Reg. No. 2382-187", 6 September 2012 (2012-09-06), XP007921955, Retrieved from the Internet <URL:http://www.regulations.gov/#!documentDetail;D=EPA-HQ-OPP-2007-1024-1504> [retrieved on 20130605] * |
ENDRIS R G ET AL: "Efficacy of Two 65% Permethrin Spot-on Formulations Against Induced Infestations of Ctenocephalides felis (Insecta: Siphonaptera) and Amblyomma americanum (Acari: Ixodidae) on Beagles", VETERINARY THERAPEUTICS, VETERINARY LEARNING SYSTEMS, TRENTON, NJ, US, vol. 4, no. 1, 1 January 2003 (2003-01-01), pages 47 - 55, XP003030811, ISSN: 1528-3593 * |
VIRBAC: "MATERIAL SAFETY DATA SHEET EFFITIX(TM) Topical Solution for Dogs", 20120424, 24 April 2012 (2012-04-24), pages 1 - 6, XP007921951 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016108117A1 (fr) * | 2014-12-30 | 2016-07-07 | Virbac | Combinaison topique de fipronil, de perméthrine et de pyriproxyfène |
Also Published As
Publication number | Publication date |
---|---|
BR112015015493B1 (pt) | 2020-11-24 |
FR3000393B1 (fr) | 2015-01-16 |
BR112015015493A2 (pt) | 2017-07-11 |
EP2938361A1 (fr) | 2015-11-04 |
BR112015015493A8 (pt) | 2019-10-22 |
AU2013368970A1 (en) | 2015-07-16 |
FR3000393A1 (fr) | 2014-07-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104202985B (zh) | 包含氟虫腈和氯菊酯的局部组合物和使用方法发明领域 | |
WO1998011780A1 (fr) | Nouvelle association parasiticide | |
EP2567618B1 (fr) | Composition pharmaceutique contenant un dérivé de N-phénylpyrazole, utilisation pour la préparation d'un médicament vétérinaire topique pour lutter contre les puces | |
US8993546B2 (en) | Parasiticidal composition | |
AU2010212672B2 (en) | Topical composition | |
EP2234492B1 (fr) | Composition pharmaceutique contenant un derive de n-phenylpyrazole et du glycofurol, utilisation pour la preparation d'un medicament veterinaire topique pour lutter contre les puces | |
AU2005100403B4 (en) | Parasiticide Composition | |
EP2207422B1 (fr) | Utilisation d'un derive de 1-n-(halo-3-pyridylmethyle)-n- methylamino-1-alkylamino-2-nitroethylene pour la preparation d'une composition pharmaceutique veterinaire topique pour lutter contre les parasites externes | |
WO2014102693A1 (fr) | Composition pharmaceutique contenant un derive de n-phenylpyrazole et de permethrine, utilisation pour la preparation d'un medicament veterinaire topique | |
WO2012107585A1 (fr) | Nouvelles compositions antiparasitaires topiques concentrees et stables | |
WO2009080909A2 (fr) | Dispositif repulsif contre les parasites des animaux domestiques | |
EP3240528B1 (fr) | Combinaison topique contenant fipronil, permethrin and pyriproxyfen | |
WO2017017091A1 (fr) | Nouvelles compositions vétérinaires pour la prévention et le traitement simultané des endoparasites et ectoparasites | |
FR3039400A1 (fr) | Nouvelles compositions veterinaires pour la prevention et le traitement simultane des endoparasites et ectoparasites | |
EP0150638A1 (fr) | Composition à base de pyréthroides pour le traitement local des parasitoses cutanées |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13826884 Country of ref document: EP Kind code of ref document: A1 |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112015015493 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2013368970 Country of ref document: AU Date of ref document: 20131220 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2013826884 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 112015015493 Country of ref document: BR Kind code of ref document: A2 Effective date: 20150626 |